27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Mesoblast Limited (NASDAQ:MESO) product rexlemestrocel-L has received Orphan Drug Destination from the U.S. Food and Drug Administration for prevention of gastrointestinal bleeding in patients with left ventricular assist device.
The Orphan Drug Act provides for granting special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
"We are very pleased that the FDA has granted our heart failure cell therapy product candidate, Revascor, Orphan Drug designation for use in patients with LVADs to prevent mucosal bleeding, including from the gastrointestinal (GI) tract,” said Mesoblast CEO Dr. Silviu Itescu in a statement. “We look forward to our upcoming meeting with the FDA to discuss a potential approval pathway under the product's existing Regenerative Medicine Advanced Therapy (RMAT) designation for this life-threatening condition."
Mesoblast shares traded higher by 6.4% to $4.97 at time of publication. The stock has a 52-week range between $8.78 and $3.35.
Related Links:
Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA
34 Stocks Moving In Monday's Pre-Market Session
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.